Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukamia or undergoing allogeneic bone narrow transplant

Clinical Microbiology and Infection

Volumn 10, Issue 3, 2004, Pages 255-257

  Castagnola, Elio ^a   Machetti, M ^b   Cappelli, B ^a   Molinari, A C ^a   Morreale, G ^a   Dodero, P ^a   Toma P ^a   Faraci, M ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Amphotericin B; Bone marrow transplant; Caspofungin; Fungal pneumonia; Leukaemia; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; TACROLIMUS; VORICONAZOLE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FANCONI ANEMIA; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; LUNG INFILTRATE; LUNG MYCOSIS; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 1642269276     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1198-743X.2004.00837.x     Document Type: Article

References (8)

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33: 1692-1696.
2. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696-709.
3. Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: Rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002; 34: 1415-1417.
4. Rubin MA, Carroll CK, Cahill BC. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002; 34: 1160-1161.
5. Leone J. Combination therapy with caspofungin and amphotericin B lipid complex. Am J Health Syst Pharm 2002; 59: 80-81.
6. Aliff TB, Maslak PG, Jurcic JG et al. Refractory aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin B. Cancer 2003; 97: 1025-1032.
7. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics (PK) of caspofungin (CAS) in pediatric patients [abstract M-896]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Washington, DC: American Society for Microbiology, 2002; 395.
8. Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34: 939-943.